Global Pulmonary Arterial Hypertension Market Analysis, Drivers, Restraints, Opportunities, Trends, Applications, and Growth Forecast: 2018 to 2029

“Global Pulmonary Arterial Hypertension Market” is an upcoming report by MarketResearch.biz. The pulmonary arterial hypertension market segmentation allows for deeper understanding and thought, to decisively assess, analyze, and study. Apart from revenues for global, regional, and country-wise segments, market revenue segmentation will be anthologized in a scrupulous manner for clear understanding and flow. The analysis will be conducted using expert opinions and inputs, as well as comprehensive primary and secondary research efforts to establish facets of the pulmonary arterial hypertension market. The global pulmonary arterial hypertension market report will be segmented on the basis of drug class as well as region and countries.

Request Covid - 19 Impact

Overview:

Pulmonary arterial hypertension is a rare, progressive disorder that’s characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. Pulmonary arteries are the blood vessels that carry blood from the right side of the heart through the lungs.

Dynamics:

Some of the factors that are projected to impact the revenue growth of the global pulmonary arterial hypertension market are the change in lifestyles, rising geriatric population figures, a robust drug pipeline and the increasing prevalence of pulmonary arterial hypertension (PAH). Several government initiatives that create awareness and offer incentives such as tax waivers, credits, assistance & support are expected to contribute to the revenue growth of the global pulmonary arterial hypertension market.

Factors that are increasing the risk of high blood pressure and hypertension are a lack of physical activity among individuals, excessive consumption of alcohol, smoking, fast food, etc. This increased blood pressure can further lead to complications such as heart attacks, strokes, and pulmonary arterial hypertension. And, this is subsequently contributing to the expansion of the global pulmonary arterial hypertension market.

In terms of drug class, market segmentation is as follows - prostacyclin and prostacyclin analogs, phosphodiesterase 5 (PDE-5), Endothelin Receptor Antagonists (ERA), and soluble Guanylate Cyclase (SGC) stimulators. The prostacyclin & prostacyclin analogs and the ERA segments accounted for significant market revenue shares in 2019 due to a significant increase in drug sales meant for treating pulmonary arterial hypertension.

Regional Analysis:

Due to the developed healthcare infrastructure that allows for advanced therapeutics to treat pulmonary arterial hypertension in the US, the market in North America accounted for the majority revenue share in 2019. Other factors that have contributed to the increased demand for PAH treatment in this region are high diagnosis rates, supportive government initiatives and a growing awareness of PAH. The market in Europe came second in terms of revenue share in 2019. This was attributed to a growing geriatric population, increased exposure to pollution and a change in lifestyles. The market in the Asia Pacific is projected to register the highest CAGR over the next 10 years due to factors such as robust economic development, booming population figures, and improving healthcare systems.

Global Market Segmentation:

By Drug Class:

• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators
• ERA
• PDE-5 

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Johnson & Johnson Services Inc. (Actelion Pharmaceuticals, Ltd.)
• Novartis International AG
• Gilead Sciences Inc.
• United Therapeutics Corporation
• GlaxoSmithKline PLC (GSK)
• Pfizer Inc.
• Dong-A ST Co. Ltd.
• Merck Sharp & Dohme Corp
• Bayer HealthCare
• Arena Pharmaceuticals